SMTL ID : 8bdn.2 (3 other biounits)

VCB in complex with compound 23

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 2.76 Å

Oligo State

hetero-1-1-2-mer

Ligands

1 x QFR: (2~{R})-3-methyl-1-[(2~{S},4~{R})-2-[(5~{R})-5-methyl-5-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]-4~{H}-1,2,4-oxadiazol-3-yl]-4-oxidanyl-pyrrolidin-1-yl]-2-(3-methyl-1,2-oxazol-5-yl)butan-1-one(Non-covalent)

QFR.1: 14 residues within 4Å: Chain A: N.16, F.25, W.37, F.40, Y.47, P.48, L.50, R.56, I.58, H.59, S.60, Y.61, H.64, W.66 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:W.37, A:W.37, A:I.58, A:Y.61, A:W.66 Hydrogen bonds: A:Y.47, A:H.59, A:Y.61, A:H.64 pi-Stacking: A:Y.47, A:Y.61

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Krieger, J. et al., Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design. Chemmedchem (2023)

Release Date

2023-02-15

Peptides

von Hippel-Lindau disease tumor suppressor: A
Elongin-B: B
Elongin-C: CD

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

B
D

C
E

D
K

von Hippel-Lindau disease tumor suppressor

Elongin-B

Elongin-C

Related Entries With Identical Sequence